CD155 and its receptors in glioma: prospects for emerging immune checkpoint inhibitors
Mingyao Huang, Youchen Cui, Xiaoqian Wang, Yang Weng, Huiyan Huang, Weiwei Su, Shan Zhao, Yan Li · 2026
Read CD155 and its receptors in glioma: prospects for emerging immune checkpoint inhibitors by Mingyao Huang, Youchen Cui, Xiaoqian Wang, Yang Weng, Huiyan Huang, Weiwei Su, Shan Zhao, Yan Li (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13390371.txt.
Description
Mingyao Huang's team reviews CD155, the polio virus sensor, and its sensors as immune checkpoint targets in glioma, a fast-moving brain cancer with a strongly damping immune setting and poor treatment response. CD155 is often run high in glioma and tunes defences through blocking sensors TIGIT and CD96 plus the switching-on sensor CD226.
Those links blunt killer T cell and natural killer cell activity while fostering control forms, helping tumours escape destruction. Immune drugs, dual-target immune drugs, and CAR-built immune cells targeting the CD155 axis are in testing. The review weighs their promise against the hurdles of breaking glioma immune damping.
Catalog record
| CREATOR | Mingyao Huang, Youchen Cui, Xiaoqian Wang, Yang Weng, Huiyan Huang, Weiwei Su, Shan Zhao, Yan Li |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 60 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |